The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention
Jiesuck Park, Jung-Kyu Han, Jeehoon Kang, In-Ho Chae, Sung Yun Lee, Young Jin Choi, Jay Young Rhew, Seung-Woon Rha, Eun-Seok Shin, Seong-Ill Woo, Han Cheol Lee, Kook-Jin Chun, DooIl Kim, Jin-Ok Jeong, Jang-Whan Bae, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim, Jiesuck Park, Jung-Kyu Han, Jeehoon Kang, In-Ho Chae, Sung Yun Lee, Young Jin Choi, Jay Young Rhew, Seung-Woon Rha, Eun-Seok Shin, Seong-Ill Woo, Han Cheol Lee, Kook-Jin Chun, DooIl Kim, Jin-Ok Jeong, Jang-Whan Bae, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim
Abstract
Background and objectives: The outcome benefits of β-blockers in chronic coronary artery disease (CAD) have not been fully assessed. We evaluated the prognostic impact of β-blockers on patients with chronic CAD after percutaneous coronary intervention (PCI).
Methods: A total of 3,075 patients with chronic CAD were included from the Grand Drug-Eluting Stent registry. We analyzed β-blocker prescriptions, including doses and types, in each patient at 3-month intervals from discharge. After propensity score matching, 1,170 pairs of patients (β-blockers vs. no β-blockers) were derived. Primary outcome was defined as a composite endpoint of all-cause death and myocardial infarction (MI). We further analyzed the outcome benefits of different doses (low-, medium-, and high-dose) and types (conventional or vasodilating) of β-blockers.
Results: During a median (interquartile range) follow-up of 3.1 (3.0-3.1) years, 134 (5.7%) patients experienced primary outcome. Overall, β-blockers demonstrated no significant benefit in primary outcome (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.63-1.24), all-cause death (HR, 0.87; 95% CI, 0.60-1.25), and MI (HR, 1.25; 95% CI, 0.49-3.15). In subgroup analysis, β-blockers were associated with a lower risk of all-cause death in patients with previous MI and/or revascularization (HR, 0.38; 95% CI, 0.14-0.99) (p for interaction=0.045). No significant associations were found for the clinical outcomes with different doses and types of β-blockers.
Conclusions: Overall, β-blocker therapy was not associated with better clinical outcomes in patients with chronic CAD undergoing PCI. Limited mortality benefit of β-blockers may exist for patients with previous MI and/or revascularization.
Trial registration: ClinicalTrials.gov Identifier: NCT03507205.
Keywords: Adrenergic beta-antagonists; Angina, stable; Percutaneous coronary intervention.
Conflict of interest statement
The authors have no financial conflicts of interest.
Copyright © 2022. The Korean Society of Cardiology.
Figures
References
- Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
- Puymirat E, Riant E, Aissaoui N, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801.
- Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5:12–20.
- Hwang D, Lee JM, Kim HK, et al. Prognostic impact of β-blocker dose after acute myocardial infarction. Circ J. 2019;83:410–417.
- Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658.
- Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002;143:301–307.
- Andersson C, Shilane D, Go AS, et al. β-Blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64:247–252.
- Bangalore S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–1349.
- Motivala AA, Parikh V, Roe M, et al. Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. JACC Cardiovasc Interv. 2016;9:1639–1648.
- Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823–827.
- Johnston DL, Gebhardt VA, Donald A, Kostuk WJ. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography. Circulation. 1983;68:1280–1289.
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
- Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol. 1995;25:1327–1332.
- Ambrosio G, Flather MD, Böhm M, et al. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart. 2011;97:209–214.
- Narahara KA Betaxolol Investigators Group. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Am J Cardiol. 1990;65:577–582.
- Rodrigues EA, Lawrence JD, Dasgupta P, et al. Comparison of bevantolol and atenolol in chronic stable angina. Am J Cardiol. 1988;61:1204–1209.
- Sorbets E, Steg PG, Young R, et al. β-Blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40:1399–1407.
- Goldberger JJ, Bonow RO, Cuffe M, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66:1431–1441.
- Park J, Han JK, Kang J, et al. Optimal dose and type of β-blockers in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2020;137:12–19.
- Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques; Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference; 2001 Apr 22-25; Long Beach, CA. place unknown: SAS User Groups; 2001.
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–3107.
- Bangalore S, Bhatt DL, Steg PG, et al. β-Blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7:872–881.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477.
- Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–974.
- Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939–953.
- Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26:615–629.
- Chung J, Han JK, Kim YJ, et al. Benefit of vasodilating β-blockers in patients with acute myocardial infarction after percutaneous coronary intervention: nationwide multicenter cohort study. J Am Heart Assoc. 2017;6:e007063.
- McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35:1719–1725.
- Chung J, Han JK, Yang HM, et al. Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry. Korean J Intern Med. 2021;36:S62–S71.
Source: PubMed